Atherosclerosis is a condition where arteries narrow due to plaque buildup, restricting blood flow and increasing the risk of cardiovascular events. It accounts for a significant portion of global cardiovascular disease (CVD) cases, which caused 20.5 million deaths in 2021, according to the World Heart Federation. With limited treatment options, there is a growing focus on better therapies, including targeted biologics and anti-inflammatory drugs. The atherosclerosis pipeline analysis by Expert Market Research highlights several promising atherosclerosis therapeutics in development. Advancements in drug delivery, genetic research, and increased R&D investment are expected to drive substantial pipeline growth in the coming years.
Major companies involved in the atherosclerosis pipeline analysis include AstraZeneca, Novartis Pharmaceuticals, and others.
Leading drugs currently in the pipeline include Pelacarsen (TQJ230), UDP-003, and others.
Breakthroughs such as lepodisiran, key industry collaborations, and cutting-edge nanoparticle drug delivery technologies are significantly accelerating growth in the atherosclerosis pipeline landscape.
The Atherosclerosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into atherosclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atherosclerosis. The atherosclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atherosclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atherosclerosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atherosclerosis.
Atherosclerosis is a condition where arteries become narrowed and hardened due to plaque buildup, primarily composed of fats, cholesterol, and inflammatory cells. This process begins when damage occurs to the arterial walls, triggering an immune response. Over time, the accumulation of fatty deposits and chronic inflammation restricts blood flow, increasing the risk of heart attacks and strokes.
Atherosclerosis treatment includes lifestyle changes, cholesterol-lowering drugs, antiplatelet agents, and anti-inflammatory therapies to reduce plaque buildup and prevent cardiovascular events. In June 2023, the U.S. Food and Drug Administration approved LODOCO (colchicine, 0.5 mg tablet) as the first anti-inflammatory drug to lower cardiac event risks in atherosclerotic cardiovascular disease by 31% on top of standard therapies.
According to the World Heart Federation, cardiovascular diseases remain a global health challenge, with 20.5 million deaths reported in 2021. Ischaemic heart disease is the leading cause of premature death in 146 countries for men and 98 for women. The United States, EU-4, the United Kingdom, Japan, and India report varied incidence rates. High-income regions show lower death rates, while Central Europe, Eastern Europe, and Central Asia continue to exhibit the highest age-standardized cardiovascular mortality.
This section of the report covers the analysis of atherosclerosis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share at 28.29% of the total atherosclerosis clinical trials. Followed by Phase III at 26.32%, Phase II at 23.68%, Phase I at 14.47%, and Early Phase I at 7.24%. This strong late-stage pipeline highlights significant progress in clinical development, offering promising therapeutic advancements and positively influencing growth and innovation in the atherosclerosis market.
The drug molecule categories covered under the atherosclerosis pipeline analysis include small molecules, monoclonal antibodies, peptides, nucleic acid-based therapies, gene therapy, and others. The atherosclerosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atherosclerosis.
Lipid-lowering therapies continue to play a pivotal role in the treatment of atherosclerosis. For example, YN001, a liposome-encapsulated formulation of Rosuvastatin calcium, is under development to enhance targeted delivery. It utilizes the CD44-active targeting ability of HPD, a liposomal component, to enrich Rosuvastatin in atherosclerotic plaques, potentially improving therapeutic outcomes and plaque stability.
The EMR report for the atherosclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atherosclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atherosclerosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atherosclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atherosclerosis drug candidates.
Pelacarsen is being sponsored by Novartis Pharmaceuticals in a Phase III rollover extension study. Pelacarsen is a liver-targeted antisense oligonucleotide designed to inhibit apolipoprotein(a) production, thereby significantly lowering Lp(a) levels. This trial is evaluating the long-term safety and tolerability of Pelacarsen in patients with elevated Lp(a) and established atherosclerotic cardiovascular disease (ASCVD).
AZD0780 is being developed by AstraZeneca and is part of a Phase II clinical trial, where it is evaluated for its effect on systolic blood pressure in patients with ASCVD or risk equivalents. AZD0780 is a PCSK9 inhibitor, working to reduce LDL cholesterol levels, thereby aiming to lower the risk of cardiovascular events like heart attacks and strokes. The study uses 24-hour ambulatory monitoring.
UDP-003, sponsored by Cyclarity Therapeutics, is currently undergoing an early-phase, placebo-controlled clinical trial to evaluate its safety, pharmacokinetics, and pharmacodynamics in healthy individuals and patients with atherosclerotic cardiovascular disease. The study aims to determine UDP-003’s potential efficacy in reducing arterial plaque burden. This investigational drug targets 7-ketocholesterol, an oxidized form of cholesterol that accumulates with age and contributes to plaque formation. Administered as an intravenous injection, UDP-003 is designed to stimulate macrophages to clear plaque by transforming foam cells back into functional immune cells, thereby promoting arterial repair and improving cardiovascular health.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Atherosclerosis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atherosclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the atherosclerosis pipeline insights.
Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline Analysis Report
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share